Lotus Pharmaceutical Co Ltd
TWSE:1795
Lotus Pharmaceutical Co Ltd
Free Cash Flow
Lotus Pharmaceutical Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Free Cash Flow
NT$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Free Cash Flow
NT$1.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
58%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Free Cash Flow
NT$226.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Free Cash Flow
NT$339.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Free Cash Flow
-NT$696.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-41%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Free Cash Flow
NT$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
Lotus Pharmaceutical Co Ltd
Glance View
Lotus Pharmaceutical Co., Ltd., nestled at the intersection of innovation and healthcare, has carved a niche in the competitive pharmaceuticals landscape. Founded in Taiwan, Lotus has evolved into a prominent player, with a strategic focus on the development, manufacturing, and distribution of high-barrier generic drugs and specialty pharmaceuticals. Its journey began as a local pharmaceutical manufacturer but rapidly expanded its horizons through well-timed acquisitions and partnerships. These strategic moves have not only broadened its portfolio but also fortified its foothold in various international markets. The company leverages cutting-edge research and development capabilities to produce cost-effective alternatives to branded medications, which require significant expertise to replicate due to complex manufacturing processes and stringent regulatory requirements. Lotus’s operations hinge on its ability to navigate the intricacies of pharmaceutical regulations and patent landscapes, enabling it to introduce generics as soon as original drug patents expire. This strategic agility allows the company to capture market share quickly and maximize its revenue potential. Lotus Commercializes its products primarily in Asia while also extending its reach to North America and Europe through a network of collaborations and partnerships. Its robust portfolio spans several therapeutic areas, including oncology, central nervous system disorders, and cardiovascular diseases, where the demand for affordable medications is acute. As a result, Lotus not only generates substantial revenue but also plays a pivotal role in enhancing healthcare accessibility and affordability across the globe.
See Also
What is Lotus Pharmaceutical Co Ltd's Free Cash Flow?
Free Cash Flow
3.3B
TWD
Based on the financial report for Sep 30, 2024, Lotus Pharmaceutical Co Ltd's Free Cash Flow amounts to 3.3B TWD.
You don't have any saved screeners yet